TMCnet News

Sensei Biotherapeutics to Participate in Citi's 2022 Virtual Immuno-Oncology Summit
[February 11, 2022]

Sensei Biotherapeutics to Participate in Citi's 2022 Virtual Immuno-Oncology Summit

BOSTON, Feb. 11, 2022 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today announced that company management will participate in Citi's 2022 Immuno-Oncology Summit.

Dr. Robert Pierce, Chief R&D Officer, will participate in a fireside chat beginning at 2:30pm ET on Wednesday, February 16, 2022. A webcast of the fireside chat will be available on the Events & Presentations section of Sensei’s website at A replay of the webcast will be on the website for approximately 90 days following the event.

About Sensei Biotherapeutics
Sensei Biotherapeutics is a biopharmaceutical company engaged in discovery, development, and delivery of next generation immunotherapies with an initial focus on treatments for cancer. Sensei has developed two unique approaches – its TMAb™ (Tumor Microenvironment Activated biologics) platform, comprising unique human mnoclonal antibodies and alpaca derived nanobodies that are selectively active in the tumor microenvironment, and its ImmunoPhage™ platform that leverages bacteriophage to drive the generation of tumor antigen-specific immune responses. Using its TMAb platform, the company has developed SNS-101, an antibody-based therapeutic targeting an immune checkpoint gene that inhibits anti-tumor immune responses called V-domain Ig suppressor of T cell activation (VISTA). Using the ImmunoPhage platform, Sensei is developing a library of ImmunoPhage, called Phortress™, with multiple tumor-associated antigens to create a personalized, yet off-the-shelf cocktail approach for treating cancer patients. The platform is designed to enable efficient, scalable and cost-effective manufacturing to support all of Sensei’s clinical programs. SNS-401-NG is an ImmunoPhage cocktail in preclinical development for the treatment of Merkel Cell Carcinoma. For more information, please visit, and follow the company on Twitter @SenseiBio and LinkedIn.

Investor Contact:
Erin Colgan
Chief Financial Officer
Sensei Biotherapeutics
[email protected]

Primary Logo

[ Back To's Homepage ]